Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02750826 · ClinicalTrials.gov registry record · Phase 3
Breast Cancer WEight Loss Study (BWEL Study)
A Phase 3 study of Breast Carcinoma, sponsored by Alliance for Clinical Trials in Oncology.
- Active
- Registry status
- Phase 3
- Development phase
- 3,177
- Enrollment target
- 20
- Study locations
NCT02750826 is a Phase 3 study of Breast Carcinoma that is active but no longer recruiting, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 3,177 participants, above the 740-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (329% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT02750826, a Phase 3 study of Breast Carcinoma, is active but no longer recruiting, sponsored by Alliance for Clinical Trials in Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 3,177 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed. This study aims to test whether overweight or obese women who take part in a weight loss program after being diagnosed with breast cancer have a lower rate of cancer recurrence as compared to women who do not take part in the weight loss program. This study will help to show whether weight loss programs should be a part of breast cancer treatment.
Conditions Studied
Interventions
- OTHER Health Education Program
- OTHER Weight Loss Intervention
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
- Fairbanks Memorial Hospital - Fairbanks
Arizona
- Kingman Regional Medical Center - Kingman
- Cancer Center at Saint Joseph's - Phoenix
- Mayo Clinic Hospital in Arizona - Phoenix
- Mayo Clinic in Arizona - Scottsdale
- University of Arizona Cancer Center-Orange Grove Campus - Tucson
- Banner University Medical Center - Tucson - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
Alabama
- Southern Cancer Center PC-Daphne - Daphne
- Southern Cancer Center PC-Mobile - Mobile
- Southern Cancer Center PC-Providence - Mobile
- Southern Cancer Center PC-Springhill - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,177 participants |
| Start Date | 2016-09-16 |
| Est. Completion | 2030-05-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02750826
The ClinicalTrials.gov registry entry for NCT02750826 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 3,177 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 740-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (329% higher). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Health Education Program is the first listed.
NCT02750826 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Alaska, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT02750826 about?
NCT02750826 is a clinical study titled "Breast Cancer WEight Loss Study (BWEL Study)". This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast canc...
What is the current status of trial NCT02750826?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 3,177 participants. The study started on 2016-09-16. Estimated completion is 2030-05-30.
What conditions does trial NCT02750826 study?
This clinical trial studies the following conditions: Breast Carcinoma.
What interventions are being tested in trial NCT02750826?
The interventions under investigation include: Health Education Program (OTHER), Weight Loss Intervention (OTHER).
Who is sponsoring clinical trial NCT02750826?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02750826 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy
ACTIVE NOT RECRUITING · Phase 3
-
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
ACTIVE NOT RECRUITING · Phase 3
-
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
COMPLETED · Phase 3
-
Surviving Daily Life
RECRUITING
-
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.